Yuva Biosciences
Yuva Biosciences is a Birmingham, Alabama-based biotech that uses its proprietary MitoNova AI platform to discover mitochondrial health compounds. It licenses its Y100 ingredient to consumer beauty brands like BosleyMD and partners with pharmaceutical companies like NorthStrive Biosciences for drug discovery in aging-related diseases.
- Company typePrivate
- Founded2019
- HeadquartersBirmingham, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Yuva Biosciences does
Yuva Biosciences is a Birmingham, Alabama-based private biotech company founded in 2019 that operates at the intersection of mitochondrial science and AI-driven drug discovery. The company's core technology is the proprietary MitoNova AI platform, which is purpose-built to predict and validate biologically active compounds that improve mitochondrial health through iterative AI-biology feedback loops where computational predictions are tested on Yuva-designed assay systems and the experimental results are fed back to retrain the model. The platform is trained on years of proprietary in-house testing data with multi-dose, multi-timepoint outcomes not available in public datasets, creating a data flywheel advantage. Yuva's flagship commercial compound is Y100, a clinically proven cosmetic active ingredient that boosts mitochondrial function and reverses visible signs of aging, supported by 10+ patents, 5+ clinical studies, and 6+ years of research.
Yuva operates a B2B licensing business model, generating revenue through licensing royalties on its proprietary compounds. The company serves two primary customer segments: (1) consumer beauty and personal care brands, where Y100 is licensed for anti-aging skincare, hair regrowth, and wellness products via partnerships with BosleyMD (Revive+ hair serum, nationally launched February 2024) and Elevai Labs (S-Series Root Renewal System, launched December 2024); and (2) pharmaceutical and biotech companies, via a co-development partnership with NorthStrive Biosciences (a PMGC Holdings subsidiary) to identify small-molecule candidates for obesity, cardiometabolic disease, and muscle preservation in GLP-1 receptor agonist patients. In July 2026, Phase III validation of the NorthStrive program yielded four compounds demonstrating up to +50% ANT1 protein expression increases.
The company is led by Co-Founder and CEO Greg Schmergel (serial entrepreneur, former Ernst & Young Entrepreneur of the Year), Scientific Founder and CSO Dr. Keshav Singh (world authority in mitochondrial biology, 100+ publications), and Co-Founder and COO Saksham Narang, with Chief Data Scientist Jeb Linton (former IBM Watson Architecture Board co-chair) and Chief Strategy Advisor Shekhar Mitra (former P&G SVP of Global Innovation) supporting AI and commercial scaling. Yuva has raised $7.5 million in seed funding (February 2024) led by VentureSouth, with offices in Birmingham, New York City, and Boston.
Yuva Biosciences firmographics
Firmographics- Name
- Yuva Biosciences
- Legal name
- Yuva Biosciences
- Website
- https://yuvabio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Yuva Biosciences is a Birmingham, Alabama-based biotech that uses its proprietary MitoNova AI platform to discover mitochondrial health compounds. It licenses its Y100 ingredient to consumer beauty brands like BosleyMD and partners with pharmaceutical companies like NorthStrive Biosciences for drug discovery in aging-related diseases.
- Ownership category
- akta.pro rank
Yuva Biosciences industry classification
Industry- Product category
- AI-Driven Mitochondrial Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)
Keywords
Where Yuva Biosciences is headquartered
LocationHeadquarters
- HQ city
- Birmingham
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Yuva Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing Royalties: Yuva Biosciences licenses its proprietary compound Y100 to consumer product companies for use in skincare, haircare, and other cosmetic products. The company also licenses technology and compounds to pharmaceutical partners for drug development.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Yuva Biosciences product offering
Product offeringCore offering
Yuva Biosciences develops proprietary compounds and an AI discovery platform that target mitochondrial health. The MitoNova AI platform identifies biologically active compounds modulating mitochondrial function, and the company licenses its lead ingredient Y100 to consumer brands for skincare and haircare products, while also partnering with pharmaceutical companies on drug discovery for obesity and cardiometabolic diseases.
Product overview
Yuva Biosciences operates as a platform-plus-products company focused on AI-driven mitochondrial health. The core of the offering is the proprietary MitoNova™ AI Platform, which discovers compounds that improve mitochondrial health through an iterative AI-biology feedback loop. Key products include Y100™, a clinically proven cosmetic active ingredient licensed to consumer product brands, and compounds used in partner products such as Revive+ by BosleyMD for hair regrowth and the S-Series Root Renewal System developed with Elevai Skincare. The company also provides compound licensing services for skincare and haircare applications.
Differentiator
Problem solved
Functional benefit
Products and services
- MitoNova AI Platform Proprietary AI platform optimized for discovering compounds that improve mitochondrial health, using iterative AI-biology feedback loops to predict and validate biologically active compounds. Licensed to pharmaceutical and biotech partners for drug discovery.
- Y100 Cosmetic Active Ingredient Proprietary cosmetic active ingredient that reverses visible signs of aging by boosting mitochondrial health. Available for licensing to consumer brands for use in skincare and haircare products.
- AI-Powered Cardiometabolic and Obesity Therapy Discovery Co-development program leveraging MitoNova AI to identify and validate small-molecule candidates targeting mitochondrial health and muscle preservation for GLP-1 receptor agonist patients. Phase III validation identified four compounds with up to +50% ANT1 expression increases.
Quantifiable outcome
- +50% ANT1 protein expression increase in skeletal muscle cells (strongest candidate C2)
- +3 more outcomes
Companies that use Yuva Biosciences
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Yuva Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature2 records
Yuva Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and secondary.
- NorthStrive BiosciencescorePartnership to develop AI-powered therapies for obesity and cardiometabolic diseases. Yuva Biosciences provides its MitoNova AI platform to identify and validate small-molecule candidates targeting mitochondrial health and muscle preservation for GLP-1 receptor agonist patients. Phase III validation successfully identified four compounds (C1, C2, C3, C4) demonstrating dose-dependent ANT1 expression increases of up to +50%.
- BosleyMDcoreBosleyMD launched Revive+ hair serum incorporating Yuva Biosciences' Y100 compound. The product was described as 'One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years'. Product is sold nationally through BosleyMD channels.
- Elevai LabssecondaryLicensing agreement for Yuva Biosciences' exosome and mitochondrial technology for use in Elevai Skincare's S-Series Root Renewal System for hair and scalp health. Initial availability through select medical aesthetics partners in the United States.
- Southern ResearchsecondaryYuva Biosciences received a Therapeutic Development Fund grant from Southern Research to address ovarian aging.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Yuva Biosciences competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-driven drug discovery company with a heavy focus on aging, age-related diseases and longevity, applying generative chemistry and target identification to develop novel small molecules. Directly comparable to Yuva's MitoNova platform in combining generative AI with biological validation against aging indications.
- Recursion Pharmaceuticals: Operates one of the most prominent AI-enabled drug discovery platforms, using high-throughput biology and machine learning to identify novel therapeutics across multiple disease areas. Most directly comparable to Yuva as a competing AI-first biotech with platform economics.
- Schrödinger, Inc. Provides computational chemistry and physics-based software for molecular discovery, used both internally for drug programs and licensed to pharma partners. Comparable to Yuva as a computational discovery platform monetized through both partnerships and proprietary pipeline assets.
- Exscientia: Pioneer in AI-driven small molecule drug discovery, using generative AI to design candidates and partner with pharma for development. Closely mirrors Yuva's model of combining an AI platform with pharma co-development partnerships to advance small-molecule therapeutics.
- BioAge Labs: Clinical-stage biotech developing therapeutics that target the biology of aging, including metabolic and obesity-related indications. Highly comparable to Yuva on the disease-focus axis (aging, cardiometabolic, muscle biology) and on the data-driven discovery approach.
Broad incumbents
- Stealth BioTherapeutics: Late-stage biotech focused on mitochondrial-targeted therapeutics for diseases involving mitochondrial dysfunction. Comparable to Yuva's pharma pipeline as a mitochondria-focused drug developer, but at clinical/commercial stage rather than AI-discovery.
- MitoQ Limited: Commercial-stage company selling mitochondria-targeted supplements and skincare products globally. Comparable to Yuva's Y100 consumer licensing business as a mitochondrial health brand monetizing the same underlying biology through consumer channels.
- Elysium Health: Consumer longevity company developing and selling scientifically validated supplements (e.g., Basis) targeting cellular health and aging pathways. Comparable to Yuva's consumer/mitochondrial focus as an established brand in the longevity consumer category.
Emerging players
- Loyal for Dogs: Clinical-stage veterinary biotech developing drugs to extend dog lifespan by targeting metabolic and aging mechanisms, with FDA engagement. Comparable to Yuva as a fellow emerging player translating aging-biology science into regulated therapeutics.
- Arcaea (formerly Sundial Foods/Arcaea): Biotech company building biologically driven ingredients and products for the beauty and personal care industry. Comparable to Yuva's Y100 licensing model as a science-first entrant selling proprietary ingredients into prestige consumer brands.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Yuva Biosciences social profiles
Digital presenceYuva Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yuva Biosciences leadership team
Management profileNumber of profiles
Profiles6 records
Yuva Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yuva Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yuva Biosciences
What does Yuva Biosciences do?
Yuva Biosciences develops proprietary compounds and an AI discovery platform that target mitochondrial health. The MitoNova AI platform identifies biologically active compounds modulating mitochondrial function, and the company licenses its lead ingredient Y100 to consumer brands for skincare and haircare products, while also partnering with pharmaceutical companies on drug discovery for obesity and cardiometabolic diseases.
Is Yuva Biosciences a public or private company?
Yuva Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Yuva Biosciences founded?
Yuva Biosciences was founded in 2019. It employs 11 to 50 people.
Where is Yuva Biosciences based?
Yuva Biosciences is headquartered in Birmingham, United States, in the North America region.
How does Yuva Biosciences make money?
One revenue line is on record: licensing Royalties.
Who are Yuva Biosciences's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Inc., Exscientia and BioAge Labs. Broad incumbents are Stealth BioTherapeutics, MitoQ Limited and Elysium Health. Emerging players are Loyal for Dogs and Arcaea (formerly Sundial Foods/Arcaea).
Does Yuva Biosciences have an API?
No public API is recorded for Yuva Biosciences.
What industry is Yuva Biosciences in?
Yuva Biosciences's product category is AI-Driven Mitochondrial Biotechnology. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its NAICS code is 541714 and its SIC code is 8731.